Skip to main content

Articles

Page 3 of 61

  1. Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure. As a reversible epigenet...

    Authors: Zaoqu Liu, Haijiao Zou, Qin Dang, Hui Xu, Long Liu, Yuyuan Zhang, Jinxiang Lv, Huanyun Li, Zhaokai Zhou and Xinwei Han
    Citation: Molecular Cancer 2022 21:220
  2. Esophageal squamous cell carcinoma (ESCC) is a common gastrointestinal malignant tumor, while the molecular mechanisms have not been fully elucidated. Multiple circular RNAs have been reported to involve in th...

    Authors: Lina Gu, Yang Sang, Xixi Nan, Yang Zheng, Fei Liu, Lingjiao Meng, Meixiang Sang and Baoen Shan
    Citation: Molecular Cancer 2022 21:217

    The Correction to this article has been published in Molecular Cancer 2023 22:19

  3. At present, there is no validated marker to identify the subpopulation of patients with advanced gastric cancer (AGC) who might benefit from neoadjuvant chemotherapy (NACT). In view of this clinical challenge,...

    Authors: Ting Guo, Xiao-Huan Tang, Xiang-Yu Gao, Yuan Zhou, Bo Jin, Zi-Qian Deng, Ying Hu, Xiao-Fang Xing, Zi-Yu Li and Jia-Fu Ji
    Citation: Molecular Cancer 2022 21:216
  4. Autoimmune disorders, including Systemic Lupus Erythematosus (SLE), are associated with increased incidence of hematological malignancies. The matricellular protein osteopontin (OPN) has been linked to SLE pat...

    Authors: Celeste Rizzello, Valeria Cancila, Sabina Sangaletti, Laura Botti, Chiara Ratti, Matteo Milani, Matteo Dugo, Francesco Bertoni, Claudio Tripodo, Claudia Chiodoni and Mario P. Colombo
    Citation: Molecular Cancer 2022 21:215
  5. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/1476-4598-13-69.

    Authors: Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone and Rossella Galati
    Citation: Molecular Cancer 2022 21:214
  6. Inactivation of the Hippo pathway promotes Yap nuclear translocation, enabling execution of a transcriptional program that induces tissue growth. Genetic lesions of Hippo intermediates only identify a minority...

    Authors: Maria E. R. Garcia-Rendueles, Gnana Krishnamoorthy, Mahesh Saqcena, Adrian Acuña-Ruiz, Giovanna Revilla, Elisa de Stanchina, Jeffrey A. Knauf, Rona Lester, Bin Xu, Ronald A. Ghossein and James A. Fagin
    Citation: Molecular Cancer 2022 21:213
  7. Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the mo...

    Authors: Yige Sun, Jie Yang, Yingbo Li, Jing Luo, Jiemei Sun, Daoshuang Li, Yuchen Wang, Kai Wang, Lili Yang, Lina Wu and Xilin Sun
    Citation: Molecular Cancer 2022 21:212
  8. The quality and quantity of tumor neoantigens derived from tumor mutations determines the fate of the immune response in cancer. Frameshift mutations elicit better tumor neoantigens, especially when they are n...

    Authors: Daniel Meraviglia-Crivelli, Helena Villanueva, Angelina Zheleva, María Villalba-Esparza, Beatriz Moreno, Ashwathi Puravankara Menon, Alfonso Calvo, Javier Cebollero, Martin Barainka, Igor Ruiz de los Mozos, Carlos Huesa-Berral and Fernando Pastor
    Citation: Molecular Cancer 2022 21:211
  9. Long noncoding RNAs (lncRNAs) have driven research focused on their effects as oncogenes or tumor suppressors involved in carcinogenesis. However, the functions and mechanisms of most lncRNAs in colorectal can...

    Authors: Xue Wang, Han Cheng, Jing Zhao, Jiuming Li, Ying Chen, Kaisa Cui, Lu Tian, Jia Zhang, Chaoqun Li, Shengbai Sun, Yuyang Feng, Surui Yao, Zehua Bian, Shenglin Huang, Bojian Fei and Zhaohui Huang
    Citation: Molecular Cancer 2022 21:210
  10. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0845-6.

    Authors: Fengting Huang, Wenying Chen, Juanfei Peng, Yuanhua Li, Yanyan Zhuang, Zhe Zhu, Chunkui Shao, Wanling Yang, Herui Yao and Shineng Zhang
    Citation: Molecular Cancer 2022 21:209
  11. Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type speci...

    Authors: Maosen Xu, Tao Zhang, Ruolan Xia, Yuquan Wei and Xiawei Wei
    Citation: Molecular Cancer 2022 21:208
  12. Exosomes are well-known key mediators of intercellular communication and contribute to various physiological and pathological processes. Their biogenesis involves four key steps, including cargo sorting, MVB f...

    Authors: Qing-Fang Han, Wen-Jia Li, Kai-Shun Hu, Jie Gao, Wen-Long Zhai, Jing-Hua Yang and Shui-Jun Zhang
    Citation: Molecular Cancer 2022 21:207
  13. Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging respon...

    Authors: Le Tong, Carlos Jiménez-Cortegana, Apple H.M. Tay, Stina Wickström, Lorenzo Galluzzi and Andreas Lundqvist
    Citation: Molecular Cancer 2022 21:206
  14. Brain cancer is regarded among the deadliest forms of cancer worldwide. The distinct tumor microenvironment and inherent characteristics of brain tumor cells virtually render them resistant to the majority of ...

    Authors: Xuchen Qi, Saurabh Kumar Jha, Niraj Kumar Jha, Saikat Dewanjee, Abhijit Dey, Rahul Deka, Pingal Pritam, Kritika Ramgopal, Weiting Liu and Kaijian Hou
    Citation: Molecular Cancer 2022 21:204
  15. Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic mod...

    Authors: Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye…
    Citation: Molecular Cancer 2022 21:201
  16. Immune checkpoint blockade has recently proven effective in subsets of patients with esophageal adenocarcinoma (EAC) but little is known regarding the EAC immune microenvironment. We determined the single cell...

    Authors: Wayne Croft, Richard P. T. Evans, Hayden Pearce, Mona Elshafie, Ewen A. Griffiths and Paul Moss
    Citation: Molecular Cancer 2022 21:200
  17. Chimeric fusion transcription factors are oncogenic hallmarks of several devastating cancer entities including pediatric sarcomas, such as Ewing sarcoma (EwS) and alveolar rhabdomyosarcoma (ARMS). Despite thei...

    Authors: Tilman L. B. Hölting, Florencia Cidre-Aranaz, Dana Matzek, Bastian Popper, Severin J. Jacobi, Cornelius M. Funk, Florian H. Geyer, Jing Li, Ignazio Piseddu, Bruno L. Cadilha, Stephan Ledderose, Jennifer Zwilling, Shunya Ohmura, David Anz, Annette Künkele, Frederick Klauschen…
    Citation: Molecular Cancer 2022 21:199
  18. Metastasis of breast cancer have caused the majority of cancer-related death worldwide. The circRNAs are associated with tumorigenesis and metastasis in breast cancer according to recent research. However, the...

    Authors: Peng Liu, Zehao Wang, Xueqi Ou, Peng Wu, Yue Zhang, Song Wu, Xiangsheng Xiao, Yuehua Li, Feng Ye and Hailin Tang
    Citation: Molecular Cancer 2022 21:198
  19. Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer, with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently, the clinical effectivene...

    Authors: Zhi Zhu, A. J. Robert McGray, Weijian Jiang, Binfeng Lu, Pawel Kalinski and Zong Sheng Guo
    Citation: Molecular Cancer 2022 21:196
  20. Papillary thyroid carcinoma (PTC) is one of the most common forms of thyroid cancer with a cure rate of over 90% after surgery. However, aggressive forms may still occur, and personalized therapeutic strategie...

    Authors: Emilie Renaud, Kristina Riegel, Rossana Romero, Kushal Suryamohan, Ute Distler, Stefan Tenzer, Arno Schad, Thomas J. Musholt and Krishnaraj Rajalingam
    Citation: Molecular Cancer 2022 21:195
  21. EGFR-TKI targeted therapy is one of the most effective treatments for lung cancer patients harboring EGFR activating mutations. However, inhibition response is easily attenuated by drug resistance, which is ma...

    Authors: Xueli Tian, Rui Wang, Tingxuan Gu, Fayang Ma, Kyle Vaughn Laster, Xiang Li, Kangdong Liu, Mee-Hyun Lee and Zigang Dong
    Citation: Molecular Cancer 2022 21:193
  22. Circular RNAs (circRNAs) act as gene expression regulators and are involved in cancer progression. However, their functions have not been sufficiently investigated in nasopharyngeal carcinoma (NPC).

    Authors: Yongzhen Mo, Yumin Wang, Yian Wang, Xiangying Deng, Qijia Yan, Chunmei Fan, Shuai Zhang, Shanshan Zhang, Zhaojian Gong, Lei Shi, Qianjin Liao, Can Guo, Yong Li, Guiyuan Li, Zhaoyang Zeng, Weihong Jiang…
    Citation: Molecular Cancer 2022 21:192
  23. In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress a...

    Authors: Nastasja Merle, Sabrina Elmshäuser, Florian Strassheimer, Michael Wanzel, Alexander M. König, Julianne Funk, Michelle Neumann, Katharina Kochhan, Frederik Helmprobst, Axel Pagenstecher, Andrea Nist, Marco Mernberger, André Schneider, Thomas Braun, Tilman Borggrefe, Rajkumar Savai…
    Citation: Molecular Cancer 2022 21:191
  24. Anaplastic thyroid carcinoma (ATC) is an extremely malignant type of endocrine cancer frequently accompanied by extrathyroidal extension or metastasis through mechanisms that remain elusive. We screened for th...

    Authors: Zongfu Pan, Tong Xu, Lisha Bao, Xiaoping Hu, Tiefeng Jin, Jinming Chen, Jianqiang Chen, Yangyang Qian, Xixuan Lu, Lu li, Guowan Zheng, Yiwen Zhang, Xiaozhou Zou, Feifeng Song, Chuanming Zheng, Liehao Jiang…
    Citation: Molecular Cancer 2022 21:190
  25. Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as the standard of care for many types of cancer, but the strategies employed have continued to evolve. Recently, much clini...

    Authors: Roger J. Daly, Andrew M. Scott, Oliver Klein and Matthias Ernst
    Citation: Molecular Cancer 2022 21:189
  26. Lung cancer is one of the fatal cancers worldwide, and over 60% of patients are lung adenocarcinoma (LUAD). Our clinical data demonstrated that DNA methylation of the promoter region of miR-126-3p was upregula...

    Authors: Lu Liang, Huiyu Cen, Jionghua Huang, Aiping Qin, Wenyan Xu, Siran Wang, Zhijun Chen, Lin Tan, Qiqi Zhang, Xiyong Yu, Xin Yang and Lingmin Zhang
    Citation: Molecular Cancer 2022 21:186
  27. Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA...

    Authors: Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao, Lei Nie, Yang Liu, Jingling Jin, Wei Wang, Heng-Huan Lee, Yuxuan Che, Enyu Dai, Guangchun Han, Ruiping Wang, Kunal Rai…
    Citation: Molecular Cancer 2022 21:185
  28. Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the prese...

    Authors: Claudia Buhigas, Anne Y. Warren, Wing-Kit Leung, Hayley C. Whitaker, Hayley J. Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J. Woodcock, Sue Merson, Fiona M. Frame, Atef Sahli, Federico Abascal, Iñigo Martincorena, G. Steven Bova…
    Citation: Molecular Cancer 2022 21:183
  29. Multiple myeloma (MM) is a heterogeneous disease with different patterns of clonal evolution and a complex tumor microenvironment, representing a challenge for clinicians and pathologists to understand and dis...

    Authors: Yuanzheng Liang, Haiyan He, Weida Wang, Henan Wang, Shaowen Mo, Ruiying Fu, Xindi Liu, Qiong Song, Zhongjun Xia and Liang Wang
    Citation: Molecular Cancer 2022 21:182
  30. Although, micropeptides encoded by non-coding RNA have been shown to have an important role in a variety of tumors processes, there have been no reports on micropeptide in renal cell carcinoma (RCC). Based on ...

    Authors: Mengwei Li, Guangxiang Liu, Xinrong Jin, Hongqian Guo, Sarra Setrerrahmane, Xindi Xu, Tiantian Li, Yunfei Lin and Hanmei Xu
    Citation: Molecular Cancer 2022 21:181
  31. Mesenchymal stem cells (MSCs) are multipotent stromal cells that can be obtained from various human tissues and organs. They can differentiate into a wide range of cell types, including osteoblasts, adipocytes...

    Authors: Zhengjun Lin, Yanlin Wu, Yiting Xu, Guoqing Li, Zhihong Li and Tang Liu
    Citation: Molecular Cancer 2022 21:179
  32. Epidermal growth factor receptor (EGFR) is both a driver oncogene and a therapeutic target in advanced head and neck squamous cell carcinoma (HNSCC). However, response to EGFR treatment is inconsistent and lac...

    Authors: Henrik Schinke, Enxian Shi, Zhongyang Lin, Tanja Quadt, Gisela Kranz, Jiefu Zhou, Hongxia Wang, Julia Hess, Steffen Heuer, Claus Belka, Horst Zitzelsberger, Udo Schumacher, Sandra Genduso, Kristoffer Riecken, Yujing Gao, Zhengquan Wu…
    Citation: Molecular Cancer 2022 21:178
  33. Given that hypoxia is a persistent physiological feature of many different solid tumors and a key driver for cancer malignancy, it is thought to be a major target in cancer treatment recently. Tumor-associated...

    Authors: Ruixue Bai, Yunong Li, Lingyan Jian, Yuehui Yang, Lin Zhao and Minjie Wei
    Citation: Molecular Cancer 2022 21:177
  34. Epigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the initiation of embryonal tumour development. In neuroblastoma, neural ...

    Authors: Carlos Jiménez, Roberta Antonelli, Mariona Nadal-Ribelles, Laura Devis-Jauregui, Pablo Latorre, Carme Solé, Marc Masanas, Adrià Molero-Valenzuela, Aroa Soriano, Josep Sánchez de Toledo, David Llobet-Navas, Josep Roma, Francesc Posas, Eulàlia de Nadal, Soledad Gallego, Lucas Moreno…
    Citation: Molecular Cancer 2022 21:175
  35. Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promis...

    Authors: Yi Zhang, Xiaomeng Liu, Yan Wang, Shihui Lai, Zhiqian Wang, Yudie Yang, Wenhui Liu, Hongquan Wang and Bo Tang
    Citation: Molecular Cancer 2022 21:174
  36. Circular RNAs (circRNAs) mediate the infiltration of tumor-associated macrophages (TAMs) to facilitate carcinogenesis and development of various types of cancers. However, the role of circRNAs in regulating ma...

    Authors: Tao Xie, Du-jiang Fu, Zhi-min Li, Dao-jun Lv, Xian-Lu Song, Yu-zhong Yu, Chong Wang, Kang-jin Li, Baoqian Zhai, Jiacheng Wu, Ning-Han Feng and Shan-Chao Zhao
    Citation: Molecular Cancer 2022 21:173
  37. Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptio...

    Authors: I. Garces de los Fayos Alonso, L. Zujo, I. Wiest, P. Kodajova, G. Timelthaler, S. Edtmayer, M. Zrimšek, S. Kollmann, C. Giordano, M. Kothmayer, H. A. Neubauer, S. Dey, M. Schlederer, B. S. Schmalzbauer, T. Limberger, C. Probst…
    Citation: Molecular Cancer 2022 21:172
  38. CDK4/6 inhibitors combined with endocrine therapy has become the preferred treatment approach for patients with estrogen receptor-positive metastatic breast cancer. However, the predictive biomarkers and mecha...

    Authors: Hongnan Mo, Xuefeng Liu, Yu Xue, Hongyan Chen, Shichao Guo, Zhangfu Li, Shuang Wang, Caiming Li, Jiashu Han, Ming Fu, Yongmei Song, Dan Li and Fei Ma
    Citation: Molecular Cancer 2022 21:171
  39. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-016-0533-3.

    Authors: Zhenyue He, Jun Yi, Xiaolong Liu, Jing Chen, Siqi Han, Li Jin, Longbang Chen and Haizhu Song
    Citation: Molecular Cancer 2022 21:170

Annual Journal Metrics